false
0000946563
0000946563
2026-09-30
2026-09-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
| Date
of Report (Date of earliest event reported) |
September 30, 2026 |
Retractable Technologies, Inc.
(Exact name of registrant
as specified in its charter)
| Texas |
|
001-16465 |
75-2599762 |
| (State or other jurisdiction |
(Commission |
(IRS Employer |
| of incorporation) |
File Number) |
Identification No.) |
| 511
Lobo Lane, Little
Elm, Texas |
75068-5295 |
| (Address of principal executive
offices) |
(Zip Code) |
| Registrant's
telephone number, including area code |
(972)
294-1010 |
None
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
| Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
| Common
Stock |
RVP |
NYSE
American |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| |
Emerging
growth company ¨ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
On September 30, 2026,
the Company issued a press release, a copy of which is attached to this Form 8-K as Exhibit 99, announcing the declaration of
a dividend to the Series II and Series III Class B Convertible Preferred Stock shareholders.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| 99 | Press release announcing the declaration of a dividend to the Series II and Series III Class B Convertible Preferred Stock shareholders. |
| 104 | Cover Page Interactive Date File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| DATE: September 30, 2026 |
RETRACTABLE TECHNOLOGIES, INC. |
| |
(Registrant) |
| |
|
|
| |
BY: |
/s/ John W. Fort III |
| |
|
JOHN W. FORT III |
| |
|
VICE PRESIDENT, CHIEF FINANCIAL OFFICER, AND CHIEF ACCOUNTING OFFICER |
Exhibit 99
RETRACTABLE TECHNOLOGIES, INC. DECLARES
DIVIDENDS TO SERIES II AND III CLASS B
PREFERRED STOCK SHAREHOLDERS
LITTLE ELM, Texas, September 30, 2026 —
Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared
dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of
$39,050.00 and $18,561.25, respectively. Dividends have accrued at $1.00 per share per annum. The dividends cover the period beginning
July 1, 2026 through September 30, 2026. The dividends will be paid on October 22, 2026 to shareholders of record as of
the close of business on October 12, 2026.
Retractable manufactures and markets VanishPoint®
and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe,
blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly
from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed
to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable
needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint®
needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general
line distributors.
For more information on Retractable, visit its
website at www.retractable.com.
Forward-looking statements in this press release
are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current
views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate.
However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from
such statements.
Factors that could cause or contribute to such
differences include, but are not limited to: tariffs; oil prices; material changes in demand; Retractable's ability to maintain liquidity;
Retractable's maintenance of patent protection; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements
and relationships; foreign trade risk; Retractable's ability to access the market; production costs; the impact of larger market players
in providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic
reports filed with the U.S. Securities and Exchange Commission.
Retractable Technologies, Inc.
John W. Fort III, 888-806-2626 or 972-294-1010
Vice President, Chief Financial Officer, and Chief
Accounting Officer
